Predictors of All-Cause In-Hospital Mortality in Patients With Malignant Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors.

IF 2.2 Q3 ONCOLOGY

World Journal of Oncology Pub Date : 2025-09-17 eCollection Date: 2025-10-01 DOI:10.14740/wjon2614

Elvis Obomanu, Tarfa Verinumbe, Tinsae Anebo, Colton Jones, Claudia Dourado

{"title":"Predictors of All-Cause In-Hospital Mortality in Patients With Malignant Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors.","authors":"Elvis Obomanu, Tarfa Verinumbe, Tinsae Anebo, Colton Jones, Claudia Dourado","doi":"10.14740/wjon2614","DOIUrl":null,"url":null,"abstract":"Background: Factors influencing in-hospital mortality in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) remain understudied, highlighting gaps in optimizing acute clinical outcomes. This study aimed to identify sociodemographic and clinical predictors of all-cause in-hospital mortality in this population.Methods: Using 2016 - 2020 data from the National Inpatient Sample (NIS), patients with malignant well-differentiated GEP-NETs were identified via the International Classification of Diseases, 10th Revision (ICD-10) codes. The primary outcome was in-hospital mortality. Sociodemographic and clinical variables (heart failure (HF), malnutrition, Charlson Comorbidity Index (CCI), and tumor site) were analyzed using multivariable logistic regression.Results: Among 5,642 patients (mean age 64, standard deviation (SD) 12.9), multivariable analysis identified HF (adjusted odds ratio (aOR) 2.09, 95% confidence interval (CI): 1.10 - 3.95), malnutrition (aOR 1.84, 95% CI: 1.29 - 2.62), pancreatic (aOR 1.52, 95% CI: 1.01 - 2.30) or colon tumors (aOR 2.31, 95% CI: 1.51 - 3.53), CCI ≥ 5 (aOR 1.49, 95% CI: 1.06 - 2.10), hypertension (aOR 0.65, 95% CI: 0.47 - 0.91) and elective admissions (aOR 0.40, 95% CI: 0.25 - 0.63) as clinically relevant factors associated with in-hospital mortality.Conclusions: Advanced age, tumor location, malnutrition, and HF may be critical mortality predictors among patients with GEP-NETs. These findings advocate for integrated care models prioritizing nutritional support, cardiovascular monitoring, and early elective interventions to improve outcomes.","PeriodicalId":46797,"journal":{"name":"World Journal of Oncology","volume":"16 5","pages":"478-486"},"PeriodicalIF":2.2000,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12479075/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14740/wjon2614","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Factors influencing in-hospital mortality in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) remain understudied, highlighting gaps in optimizing acute clinical outcomes. This study aimed to identify sociodemographic and clinical predictors of all-cause in-hospital mortality in this population.

Methods: Using 2016 - 2020 data from the National Inpatient Sample (NIS), patients with malignant well-differentiated GEP-NETs were identified via the International Classification of Diseases, 10th Revision (ICD-10) codes. The primary outcome was in-hospital mortality. Sociodemographic and clinical variables (heart failure (HF), malnutrition, Charlson Comorbidity Index (CCI), and tumor site) were analyzed using multivariable logistic regression.

Results: Among 5,642 patients (mean age 64, standard deviation (SD) 12.9), multivariable analysis identified HF (adjusted odds ratio (aOR) 2.09, 95% confidence interval (CI): 1.10 - 3.95), malnutrition (aOR 1.84, 95% CI: 1.29 - 2.62), pancreatic (aOR 1.52, 95% CI: 1.01 - 2.30) or colon tumors (aOR 2.31, 95% CI: 1.51 - 3.53), CCI ≥ 5 (aOR 1.49, 95% CI: 1.06 - 2.10), hypertension (aOR 0.65, 95% CI: 0.47 - 0.91) and elective admissions (aOR 0.40, 95% CI: 0.25 - 0.63) as clinically relevant factors associated with in-hospital mortality.

Conclusions: Advanced age, tumor location, malnutrition, and HF may be critical mortality predictors among patients with GEP-NETs. These findings advocate for integrated care models prioritizing nutritional support, cardiovascular monitoring, and early elective interventions to improve outcomes.

查看原文本刊更多论文

恶性高分化胃肠胰腺神经内分泌肿瘤患者全因住院死亡率的预测因素

背景：影响高分化胃肠胰神经内分泌肿瘤（GEP-NETs）患者住院死亡率的因素仍未得到充分研究，突出了优化急性临床结果的差距。本研究旨在确定该人群中全因住院死亡率的社会人口学和临床预测因素。方法：利用2016 - 2020年国家住院患者样本（NIS）的数据，通过国际疾病分类第十版（ICD-10）代码对恶性高分化GEP-NETs患者进行鉴定。主要终点是住院死亡率。采用多变量logistic回归分析社会人口学和临床变量（心力衰竭（HF）、营养不良、Charlson合并症指数（CCI）和肿瘤部位）。结果：在5,642例患者（平均年龄64岁，标准差（SD） 12.9）中，多变量分析确定HF（校正优势比（aOR） 2.09, 95%可信区间（CI）： 1.10 - 3.95）、营养不良（aOR 1.84, 95% CI: 1.29 - 2.62）、胰腺（aOR 1.52, 95% CI: 1.01 - 2.30）或结肠肿瘤（aOR 2.31, 95% CI: 1.51 - 3.53）、CCI≥5 （aOR 1.49, 95% CI: 1.06 - 2.10）、高血压（aOR 0.65, 95% CI: 0.47 - 0.91）和择期住院（aOR 0.40, 95% CI: aOR 0.40）。0.25 - 0.63)是与住院死亡率相关的临床相关因素。结论：高龄、肿瘤位置、营养不良和心衰可能是GEP-NETs患者死亡率的关键预测因素。这些发现提倡综合护理模式，优先考虑营养支持、心血管监测和早期选择性干预，以改善结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World Journal of Oncology ONCOLOGY-

CiteScore

6.10

自引率

15.40%

发文量

期刊介绍： World Journal of Oncology, bimonthly, publishes original contributions describing basic research and clinical investigation of cancer, on the cellular, molecular, prevention, diagnosis, therapy and prognosis aspects. The submissions can be basic research or clinical investigation oriented. This journal welcomes those submissions focused on the clinical trials of new treatment modalities for cancer, and those submissions focused on molecular or cellular research of the oncology pathogenesis. Case reports submitted for consideration of publication should explore either a novel genomic event/description or a new safety signal from an oncolytic agent. The areas of interested manuscripts are these disciplines: tumor immunology and immunotherapy; cancer molecular pharmacology and chemotherapy; drug sensitivity and resistance; cancer epidemiology; clinical trials; cancer pathology; radiobiology and radiation oncology; solid tumor oncology; hematological malignancies; surgical oncology; pediatric oncology; molecular oncology and cancer genes; gene therapy; cancer endocrinology; cancer metastasis; prevention and diagnosis of cancer; other cancer related subjects. The types of manuscripts accepted are original article, review, editorial, short communication, case report, letter to the editor, book review.